Towards microRNA-based therapeutics for diabetic nephropathy

Diabetologia

Volumn 56, Issue 3, 2013, Pages 444-456

  Alvarez, M L ^a   Distefano, J K ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

ASOs; Chronic kidney disease; Diabetic nephropathy; LNA; MicroRNA based therapeutics; MicroRNAs; Review

Indexed keywords

2' FLUORO; 2' O METHOXYETHYL; ANTAGOMIR; ANTAGOMIR 122; ANTIDIABETIC AGENT; ANTISENSE OLIGONUCLEOTIDE; DOUBLE STRANDED RNA; LOCKED NUCLEIC ACID; MICRORNA; MICRORNA 192; MICRORNA 21; MICRORNA 217; MICRORNA 377; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RNA; UNCLASSIFIED DRUG;

BINDING AFFINITY; BINDING SITE; BIOACCUMULATION; BIOGENESIS; DIABETIC NEPHROPATHY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DOSE RESPONSE; DOWN REGULATION; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GENE TARGETING; HUMAN; LOW DRUG DOSE; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

DIABETIC NEPHROPATHIES; HUMANS; MICRORNAS; MODELS, BIOLOGICAL; RENAL INSUFFICIENCY, CHRONIC;

EID: 84878371154     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2768-x     Document Type: Review

References (94)

1. Caramori ML, Mauer M (2003) Diabetes and nephropathy. Curr Opin Nephrol Hypertens 12:273-282
2. Gray SP, Cooper ME (2011) Alleviating the burden of diabetic nephropathy. Nat Rev Nephrol 7:71-73
3. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ (2006) The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 55:1463-1469
4. Thomas MC, Groop PH, Tryggvason K (2012) Towards understanding the inherited susceptibility for nephropathy in diabetes. Curr Opin Nephrol Hypertens 21:195-202
5. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG (2006) Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 69:2057-2063
6. Kanwar YS, Sun L, Xie P, Liu F, Chen S (2011) A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol Mech Dis 6:395-423
7. Blumenthal SS (2011) Evolution of treatment for diabetic nephropathy: historical progression from RAAS inhibition and onward. Postgrad Med 123:166-179
8. Bichu P, Nistala R, Khan A, Sowers JR, Whaley-Connell A (2009) Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag 5:129-140
9. Ayodele OE, Alebiosu CO, Salako BL (2004) Diabetic nephropathy - a review of the natural history, burden, risk factors and treatment. J Natl Med Assoc 96:1445-1454
10. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462
11. Kato M, Zhang J, Wang M, Rossi JJ et al (2007) MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A 104:3432-3437
12. Kato M, Putta S, Wang M et al (2009) TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 11:881-889
13. Kato M, Arce L, Wang M, Putta S, Lanting L, Natarajan R (2011) A microRNA circuit mediates transforming growth factor-beta1 autoregulation in renal glomerular mesangial cells. Kidney Int 80:358-368
14. Putta S, Lanting L, Sun G, Lawson G, Kato M, Natarajan R (2012) Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol 23:458-469
15. Wang Q, Wang Y, Minto AW et al (2008) MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J 22:4126-4135
16. Kim DH, Sætrom P, Snove O, Rossi JJ (2008) MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci U S A 42:16230-16235
17. Fabian MR, Cieplak MK, Frank F et al (2011) miRNA-mediated deadenylation is orchestrated by GW182 through two conserved motifs that interact with CCR4-NOT. Nat Struct Mol Biol 18:1211-1217
18. Huntzinger E, Izaurralde E (2011) Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 12:99-110
19. Tang X, Tang G, Ozcan S (2008) Role of microRNAs in diabetes. Biochim Biophys Acta 1179:697-701
20. Kato M, Park JT, Natarajan R (2012) MicroRNAs and the glomerulus. Exp Cell Res 18:993-1000
21. Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN (2004) The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev 18:3016-3027
22. Lee Y, Kim M, Han J et al (2004) MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23:4051-4060
23. Friedman RC, Farh KK, Burge CB, Bartel DP (2009) Most mammalian mRNas are conserved targets of microRNAs. Genome Res 19:92-105
24. Shi S, Yu L, Chiu C et al (2008) Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J Am Soc Nephrol 19:2159-2169
25. Harvey SJ, Jarad G, Cunningham J et al (2008) Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J Am Soc Nephrol 19:2150-2158
26. Ho J, Ng KH, Rosen S et al (2008) Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury. J Am Soc Nephrol 19:2069-2075
27. Zhdanova O, Srivastava S, Di L et al (2011) The inducible deletion of Drosha and microRNAs in mature podocytes results in a collapsing glomerulopathy. Kidney Int 80:719-730
28. Kato M, Wang L, Putta S, Wang M, Yuan H, Sun G (2010) Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells. J Biol Chem 285:34004-34015
29. Long J, Wang Y, Wang W, Chang BH, Danesh FR (2011) MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J Biol Chem 286:11837-11848
30. Mogyorosi A, Ziyadeh FN (1999) GLUT1 and TGF-beta: the link between hyperglycaemia and diabetic nephropathy. Nephrol Dial Transplant 14:2827-2829
31. Sun L, Zhang D, Liu F et al (2011) Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192. J Pathol 225:364-377
32. Kim YK, Yeo J, Kim B, Ha M, Kim VN (2012) Short structured RNAs with low GC content are selectively lost during extraction from a small number of cells. Mol Cell 46:893-895
33. van Rooij E, Marshall WS, Olson EN (2008) Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res 103:919-928
34. Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S (2012) Inhibition of microRNA function by antimiR oligonucleotides. Silence 3:1-17
35. Ebert MS, Sharp PA (2010) MicroRNA sponges: progress and possibilities. RNA 11:2043-2050
36. Park CY, Choi YS, McManus MT (2010) Analysis of microRNA knockouts in mice. Hum Mol Genet 19:R169-R175
37. Ho J, Kreidberg JA (2012) MicroRNAs in renal development. Pediatr Nephrol. doi: 10.1007/s00467-012-2204-y
38. Ho JJ, Marsden PA (2008) Dicer cuts the kidney. J Am Soc Nephrol 11:2043-2046
39. Ho J, Pandey P, Schatton T, Sims-Lucas S, Khalid M, Frank MH (2011) The pro-apoptotic protein Bim is a microRNA target in kidney progenitors. J Am Soc Nephrol 22:1053-1063
40. Nagalakshmi VK, Ren Q, Pugh MM, Valerius MT, McMahon AP, Yu J (2011) Dicer regulates the development of nephrogenic and ureteric compartments in the mammalian kidney. Kidney Int 79:317-330
41. Sequeira-Lopez ML, Weatherford ET, Borges GR, Monteagudo MC, Pentz ES, Harfe BD (2010) The microRNA-processing enzyme dicer maintains juxtaglomerular cells. J Am Soc Nephrol 21:460-467
42. Wei Q, Bhatt K, He HZ, Mi QS, Haase VH, Dong Z (2010) Targeted deletion of Dicer from proximal tubules protects against renal ischemia-reperfusion injury. J Am Soc Nephrol 21:756-761
43. Poy MN, Eliason L, Krutzfeldt J et al (2004) A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432:226-230
44. Poy MN, Hausser J, Trajkovski M et al (2009) miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci U S A 106:5813-5818
45. Chau BN, Xin C, Hartner J et al (2012) MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med 4:121ra18
46. Ebert MS, Neilson JR, Sharp PA (2007) MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 4:721-726
47. Broderick JA, Zamore PD (2011) MicroRNA therapeutics. Gene Ther 18:1104-1110
48. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB (2003) Prediction of mammalian microRNA targets. Cell 115:787-798
49. Dey N, Das F, Mariappan MM et al (2011) MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. J Biol Chem 286:25586-25603
50. Mahimainathan L, Das F, Venkatesan B, Choudhury GG (2006) Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN. Diabetes 55:2115-2125
51. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P (2007) MicroRNA-133 controls cardiac hypertrophy. Nat Med 13:613-618
52. Esau CC (2008) Inhibition of microRNA with antisense oligonucleotides. Methods 44:55-60
53. Hutvagner G, Simard MJ, Mello CC, Zamore PD (2004) Sequence-specific inhibition of small RNA function. PLoS Biol 2:E98
54. Meister G, Landthaler M, Dorsett Y, Tuschl T (2004) Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 10:544-550
55. Davis S, Lollo B, Freier S, Esau C (2006) Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res 34:2294-2304
56. Orom UA, Kauppinen S, Lund AH (2006) LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 372:137-141
57. Vermeulen A, Robertson B, Dalby AB, Marshall WS, Karpilow J, Leake D (2007) Double-stranded regions are essential design components of potent inhibitors of RISC function. RNA 13:723-773
58. Krutzfeldt J, Rajewsky N, Braich R et al (2005) Silencing of microRNAs in vivo with 'antagomirs'. Nature 438:685-689
59. Elmen J, Lindow M, Schutz S et al (2008) LNA-mediated microRNA silencing in non-human primates. Nature 452:896-899
60. Davis S, Propp S, Freier SM et al (2009) Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res 37:70-77
61. Esau C, Davis S, Murray SF et al (2006) miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3:87-98
62. Janssen HL, Reesink HW, Zeuzem S et al (2011) A randomized, doubleblind, placebo controlled safety and anti-viral proof of concept study of miravirsen, an oligonucleotide targeting miR-122, in treatment naive patients with genotype 1 chronic HCV infection. Hepatology 54(Suppl):1430A
63. van Rooij E, Purcell AL, Levin AA (2012) Developing microRNA therapeutics. Circ Res 110:496-507
64. Doench JG, Petersen CP, Sharp PA (2003) siRNAs can function as miRNAs. Genes Dev 17:438-442
65. Karolina DS, Wintour EM, Bertram J, Jeyaseelan K (2010) Riboregulators in kidney development and function. Biochimie 92:217-225
66. Takabatake Y, Isaka Y, Mizui M et al (2005) Exploring RNA interference as a therapeutic strategy for renal disease. Gene Ther 12:965-973
67. Esau CC, Monia BP (2007) Therapeutic potential for microRNAs. Adv Drug Deliv Rev 59:101-114
68. Grimm D, Wang L, Lee JS et al (2010) Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest 120:3106-3119
69. Grimm D, Streetz KL, Jopling CL et al (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441:537-541
70. An DS, Qin FX, Auyeung VC et al (2006) Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol Ther 14:494-504
71. Giering JC, Grimm D, Storm TA, Kay MA (2008) Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 16:1630-1636
72. Suhy DA, Kao SC, Mao T et al (2012) Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model. Mol Ther 20:1737-1749
73. Boudreau RL, Martins I, Davidson BL (2009) Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther 17:169-175
74. Zeng Y, Wagner EJ, Cullen BR (2002) Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 9:1327-1333
75. Hu T, Fu Q, Chen P, Ma L, Sin O, Guo D (2009) Construction of an artificial microRNA expression vector for simultaneous inhibition of multiple genes in mammalian cells. Int J Mol Sci 10:2158-2168
76. Bader AG, Brown D, Winkler M (2010) The promise of microRNA replacement therapy. Cancer Res 70:7027-7030
77. Scherr M, Venturini L, Eder M (2010) Lentiviral vector-mediated expression of pre-miRNAs and antagomiRs. Methods Mol Biol 614:175-185
78. Langlois RA, Shapiro JS, Pham AM, tenOever BR (2012) In vivo delivery of cytoplasmic RNA virus-derived miRNAs. Mol Ther 20:367-375
79. Molitoris BA, Dagher PC, Sandoval RM et al (2009) siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 20:1754-1764
80. Wolfrum C, Shi S, Jayaprakash KN et al (2007) Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25:1149-1157
81. Yuan H, Lanting L, Xu ZG et al (2008) Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes. Am J Physiol Renal Physiol 295:F605-F617
82. Gregory PA, Bert AG, Paterson EL et al (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10:593-601
83. Zarjou A, Yang S, Abraham E, Agarwal A, Liu G (2011) Identification of a microRNA signature in renal fibrosis: role of miR-21. Am J Physiol Renal Physiol 301:F793-F801
84. Du B, Ma LM, Huang MB et al (2010) High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett 584:811-816
85. Wang B, Komers R, Carew R et al (2012) Suppression of microRNA-29 expression by TGF-beta1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol 23:252-265
86. Long J, Wang Y, Wang W, Chang BH, Danesh FR (2010) Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J Biol Chem 30:23457-23465
87. Wang B, Koh P, Winbanks C et al (2011) miR-200a prevents renal fibrogenesis through repression of TGF-beta2 expression. Diabetes 60:280-287
88. Zhang Z, Luo X, Ding S et al (2012) MicroRNA-451 regulates p38 MAPK signaling by targeting of Ywhaz and suppresses the mesangial hypertrophy in early diabetic nephropathy. FEBS Lett 586:20-26
89. Fu Y, Zhang Y, Wang Z et al (2010) Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy. Am J Nephrol 32:581-589
90. Duisters RF, Tijsen AJ, Schroen B et al (2009) miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 104:170-178
91. Krutzfeldt J, Kuwajima S, Braich R et al (2007) Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res 35:2885-2892
92. Rayner KJ, Esau CC, Hussain FN et al (2011) Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478:404-407
93. Obad S, dos Santos CO, Petri A et al (2011) Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 43:371-378
94. Lanford RE, Hildebrandt-Eriksen ES, Petri A et al (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327:198-201